Lexaria Bioscience Corp.
100-740 McCurdy Road, Kelowna
British Columbia, Canada, V1X 2P7
May 4, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F. Street, N.E.
Washington, D.C. 20549
Attention: Tyler Howes
Re: | Lexaria Bioscience Corp |
| Registration Statement on Form S-1, as amended |
| Initially filed on April 3, 2023, as amended on April 28, 2023 |
| File No. 333-271096 (the “Registration Statement”) |
| Withdrawal Request for Acceleration |
Ladies and Gentlemen:
We hereby request the withdrawal of our request for acceleration, dated May 3, 2023, of the effective date of the Registration Statement on Form S-1, as amended (File No. 333-271096) that was requested to become effective at 9:00 a.m. Eastern Time, on May 5, 2023, or as soon thereafter as practicable. We hereby respectfully withdraw this acceleration request at this time.
Should any member of the staff of the Commission have any questions or comments with respect to this request, please contact our counsel, Sichenzia Ross Ference LLP, attention: Avital Perlman, Esq. at (212) 930-9700.
| Very truly yours, |
| |
|
|
| |
| LEXARIA BIOSCIENCE CORP |
| |
|
|
| |
By: | /s/ Christopher Bunka |
| |
| Christopher Bunka |
| |
| Chief Executive Officer |
| |
